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The estrogen receptor and breast cancer
It has long been known that ovarian production of the sex
steroid hormone, estrogen, affects growth, differentiation,
and function of the mammary gland. Estrogen mediates its
effects by binding to its receptors, estrogen receptor
(ER)-α and ER-β. Because ER-α was the first receptor
subtype to be identified in the breast, most studies have
focused on the biological role of ER-α in the mammary
gland. It has recently been shown that ER-β is also
expressed in breast cancer, but its function remains elusive
[1]. Classically, ER-α is thought to function as a ligand-acti-
vated transcription factor. By interacting with estrogen-
response elements contained in the promoter region of
specific genes, modulation of gene expression ultimately
results in the biological effects of estrogen. Extracellular
signals can also stimulate ER-α-mediated transcription in
the absence of estrogen. In recent years, emerging evi-
dence has revealed that a role for ER-α is to affect gene
expression in the absence of direct DNA binding. For
example, liganded ER-α can influence gene expression by
associating with other transcription factors without binding
directly to DNA. Despite the clear understanding of the
genomic mechanism of estrogen action, it is also postu-
lated that estradiol can exert nongenomic effects on cell
biology by interacting with other proteins, including a puta-
tive membrane estrogen receptor, growth factor receptors,
and intermediate cell signaling molecules [2–4].
Clinically, breast cancers have been classified as either
ER-α-positive or ER-α-negative. While patients with ER-α-
positive tumors have a slightly better survival rate than
patients with ER-α-negative tumors, expression of ER-α is
more useful as a predictive factor for response to
endocrine therapy. Over half of patients with tumors posi-
tive for both ER-α and the progesterone receptor respond
to therapy, such as tamoxifen, that is designed to interrupt
the function of ER-α [5].
Clues from in vitro studies: expression of 
ER-α α in ER-α α-negative breast cancer cells
Despite the clear clinical benefit for the interruption of ER-α
function in breast cancer cells, the precise mechanism of
ER-α action is still not completely understood. To clarify
the role of estrogen and ER-α in growth responses, investi-
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In breast cancer, interruption of estrogen receptor (ER)-α function is an effective therapeutic strategy.
Despite the clinical benefit of interruption of ER-α function, the precise biological action of ER-α in
breast tumors is not completely understood. Results of a recent study show that ER-α promotes
growth of breast cancer cells by targeting expression of signaling components of the insulin-like
growth factor system. Intriguingly, the authors of this study raise the possibility that unliganded ER-α
itself may affect gene expression and breast cancer biology, and they suggest a potential mechanism
for ER-α to stimulate proliferation in breast cancer.
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gators have attempted to express ER-α in breast cancer
cell lines to test the hypothesis that maintenance of ER-α
expression in breast tumors would restore estrogen
responsiveness and tumor sensitivity to endocrine therapy.
In 1992, Jiang and Jordan expressed ER-α in the ER-nega-
tive breast cancer cell line MDA-MB-231 [6]. Paradoxically,
they discovered that estradiol inhibited, rather than stimu-
lated, cell proliferation. In spite of these findings, both the
action of an estrogen-responsive reporter construct and
the expression of an endogenous estrogen-responsive
gene could be stimulated by estrogen. In the same year,
Garcia et al. demonstrated that MDA-MB-231 cells trans-
fected with ER-α had decreased metastatic potential in the
presence of estradiol when injected into the tail vein of
athymic, ovariectomized nude mice [7]. Subsequent
studies that introduced ER-α into breast epithelial cell lines
that do not express the receptor have shown similar
inhibitory effects of estradiol on cell growth [8–10].
However, expression of ER-α in ER-α-negative breast
cancer cell lines does not appear to simulate ER-α func-
tion. Thus, the mechanism of ER-α function in breast
cancer cells has not been elucidated by these studies.
Oesterreich and her colleagues report the creation of a
MCF7 cell line that is unresponsive to estrogen [11]. The
MCF7 parent cells are ER-α-positive and proliferate in
response to estradiol. After starving the cells of estrogen
for nine months, the MCF7 cells no longer expressed ER-
α or proliferated in response to estradiol. Compared to
other studies, Oesterreich et al. are the first authors to
demonstrate that stable expression of ER-α in a hormon-
ally unresponsive breast cancer cell line re-established
estrogen control over proliferation. Why did the introduc-
tion of ER-α into ER-negative breast cancer cells in
Oesterreich’s study reconstitute estrogen-dependent
growth, while previous studies have shown growth inhibi-
tion by estrogen? These conflicting results show that cell-
dependent effects of estradiol do not depend solely on
ER-α expression. The cellular pool of regulatory factors
probably influence transcriptional activity of ER-α, and
determine the pattern of gene expression. The cells used
in Oesterreich’s study were initially derived from cells pos-
sessing an ER-α-positive, hormonally responsive pheno-
type. In contrast, MDA-MB-231 cells are not ER-positive
or hormonally responsive to estrogen. Even though the
MCF7 cells used in the study did not express ER-α, the
cells must express essential endogenous coregulatory
factors that are required for induction of genes involved in
estradiol-induced proliferation. What are the genes regu-
lated by estradiol in this system?
The insulin-like growth factor signaling
system is a target of ER-α α action
Intriguingly, Oesterreich et al. found that expression of
ER-α was directly correlated with expression of the key
components of the insulin-like growth factor (IGF) signal-
ing system, including the type 1 IGF-receptor and insulin-
receptor substrate-1 [11]. Considerable crosstalk has
already been documented between the signaling path-
ways of estrogen and the IGFs [12]. A potent mitogen,
IGF-I, in breast cancer cells can act synergistically with
estrogen to stimulate ER-α-positive breast cancer cell pro-
liferation [13]. It has also been suggested that signaling
components of the IGF-I system are regulated by estrogen
[14]. Here, loss of ER-α was associated with decreased
expression of proteins in the IGF-I signaling system, dimin-
ished IGF signal transduction, and no growth response to
estrogen or IGF-I. Re-expression of ER-α in these cells
restored expression of molecules critical to IGF signaling
as well as the proliferative response to estrogen. These
results show that ER-α is a critical regulator of IGF-I-
induced proliferation. In the absence of ER-α, key compo-
nents of the IGF signaling pathway are lost. Thus, one way
that ER-α can stimulate breast cancer growth is by main-
taining and regulating responsiveness to the IGFs.
Even though re-introduction of ER-α into the cells restored
the hormone-responsive proliferative phenotype, the cells
did not completely reconstitute the ER-α phenotype. For
example, estrogen treatment failed to induce expression of
a key endogenous estrogen-responsive gene, the proges-
terone receptor gene. Since the cells were derived from
MCF7 cells that have been shown to induce progesterone
receptor expression following estrogen treatment, one
would hypothesize that the cells would express the proper
combination of coregulatory factors required for induction
of the progesterone receptor gene. Thus, expression of
ER-α in the ER-α-negative breast cancer cell line used by
Oesterreich  et al. [11] was still not able to restore all
hormone-dependent features of estrogen.
This study also highlights a paradox concerning the bio-
logical role of ER-α in breast tissue. Cells expressing ER-α
require the receptor for growth and can be growth-
retarded by inhibition of the receptor. However, cells that
originally expressed ER-α in Oesterreich’s study [11], and
were subsequently selected to lose its expression,
appeared to have a growth advantage. It is possible that
other growth regulatory pathways were upregulated while
cells were selected for the loss of ER-α. For example, in
human breast cancer specimens, ER-α expression corre-
lates inversely with epidermal growth factor receptor
(EGFR). A study using MCF7 cells overexpressing EGFR
demonstrated that cell growth rate could be augmented
by omitting estrogen from the growth media, indicating
that ER-α can be a growth inhibitor under some circum-
stances [15]. Recently, hyperactivation of mitogen-
activated protein kinase was shown to downregulate ER-α
expression in breast cancer cells that were overexpressing
EGFR [16]. Considering this, perhaps other growth stimu-
latory pathways, such as the epidermal growth factor
system, became upregulated in the ER-α-negative cellsBreast Cancer Research    Vol 4 No 2 Gross and Yee
used in Oesterreich’s study [11] and provided an alterna-
tive growth stimulus for estrogen and the IGF-I system.
Does ER-α α affect gene expression in the
absence of estrogen?
Since ER-α-positive tumors generally exhibit a less
aggressive phenotype than ER-α-negative tumors, ER-α is
considered to be a differentiation marker in breast cancer.
While Oesterreich et al. showed that re-expression of the
receptor restored estrogen- and IGF-mediated growth,
their data also suggested that re-expression of ER-α
tended to suppress proliferation compared to cells that
were selected to lose ER-α expression [11]. The observa-
tion that unliganded ER-α affected gene expression and
biological function shows that ER-α itself can influence
breast cancer cells, even in the absence of estrogen.
Although it is possible that low concentrations of estrogen
in the media were responsible for the restored gene
expression, it seems unlikely because the cells were main-
tained in serum stripped of endogenous steroids. A previ-
ous study has shown that ligand binding to ER-α is not
required for receptor dimerization or binding of the recep-
tor to its response elements [17]. Recent findings have
also suggested that ER-β and ER-α have ligand-indepen-
dent effects on motility and migration when expressed in
MDA-MB-231 breast cancer cells [18].
Although the biological effects of estrogens on the breast
are well known, the specific targets of ER-α to promote
growth are largely unknown. Oesterreich et al. have pro-
vided two pieces of evidence suggesting how ER-α stimu-
lates proliferation in breast cancer cells [11]. First, the
components of the IGF-I signaling system are targets of
ER-α action. Cells that lose ER-α expression also lose the
IGF signaling pathway. These results provide the clearest
demonstration of the crosstalk between estrogen and the
IGF-I pathway. Second, ligand-independent actions of
ER-α on cell biology are suggested by the finding that
expression of the type 1 IGF-receptor and insulin-receptor
substrate-1 were restored when ER-α expression was
restored. It also appears that cells which have lost ER-α
expression grow faster than their ER-α-positive parent
cells. One possible explanation for this finding is that unli-
ganded ER-α may affect expression of genes involved in
proliferation or differentiation. Oesterreich et al. have
clearly shown that expression of ER-α by itself influences
expression of IGF signaling components, and that activa-
tion of receptor further stimulates gene expression [11].
Are there an opposing set of growth inhibitory genes that
are repressed by activation of ER-α? Indeed, the idea that
estrogen functions to cancel growth inhibitory signals has
also been suggested by another recent study [19].
The results of Oesterreich et al. [11] challenge the dogma
that ER-α only depends on ligand to affect gene expression,
and introduce the possibility that unliganded ER-α itself may
have important biological effects. Clinically, this suggests
that inhibition of ER-α function could have substantially dif-
ferent biological effects than loss of ER-α expression.
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